Tom Brady Partners With eMed to Lead GLP-1 Wellness Program

Seven-time Super Bowl champion Tom Brady is taking on a new role as Chief Wellness Officer at telehealth startup eMed, with a focus on weight-loss medication.

The demand for weight-loss medication in the United States is skyrocketing. However, access remains a major hurdle. Only about 43 percent of large U.S. companies currently cover these drugs, often citing the immense cost.

eMed promises to solve this by offering a subscription-based solution. For $139 per month, consumers are connected with doctors who can prescribe Wegovy or other newer pill options. Brady’s duty will be to promote these oral choices, making them seem like a natural part of a healthy lifestyle rather than a severe medical intervention.

Many people think of GLP-1s as weekly injections, but this is changing. eMed is getting ready for growth as more oral GLP-1 pills enter the market. These weight-loss pills are easier to use than injections and work by helping people feel full and reducing intake. For many Americans, taking a daily pill is simpler than giving themselves a shot.

Linda Yaccarino, CEO of eMed, says Tom Brady is a great match for the role. She believes GLP-1s are creating a major change in healthcare and says Brady’s focus on discipline and performance is exactly what this new stage of GLP-1 care needs.

The partnership comes as popular GLP-1 drugs like Wegovy and Zepbound are criticized for being expensive and often not covered by insurance. eMed helps employers control these costs through programs that include doctor-led evaluations and careful dosing. Brady’s role in this is to connect high-performance habits with everyday health. On social media, Brady said everyone should have access to treatments that improve health, adding that eMed offers a comprehensive program with real potential for long-term change.

For Tom Brady, this partnership is about much more than lending his name to a brand. Throughout his more than two-decade NFL career, Brady was known for his intense focus on longevity, often crediting his success to strict discipline around diet, training, sleep, and recovery. His well-known TB12 approach emphasized consistency, prevention, and long-term health, allowing him to compete at the highest level well into his 40s, an uncommon feat in professional football.

That same commitment to sustainable wellness now guides his role at eMed. Rather than promoting quick fixes, Brady is aligning himself with a healthcare model that emphasizes careful medical guidance, healthy habits, and long-term results. His involvement reflects a personal belief that health should be treated as an ongoing practice, not a short-term solution, which closely matches eMed’s mission to make effective treatments more accessible and responsibly managed.

In his new role, Brady will help raise awareness of eMed’s telehealth services and promote a more disciplined, sustainable approach to wellness. His experience with performance, consistency, and recovery aligns closely with the company’s mission to support healthier lifestyles through medical care and guidance.

eMed primarily works with employers to help manage the high costs associated with GLP-1 weight-loss treatments. By partnering with companies and their health plans, eMed aims to make these in-demand medications more accessible to American workers, reducing financial barriers while maintaining medical oversight and quality care.

Brady is betting that his reputation for being great will help the healthcare industry as the face of weight-loss drugs. For millions of Americans struggling with obesity or metabolic health, seeing an elite athlete back these treatments could reduce the stigma which is often associated with weight-loss drugs. With the launch of GLP-1 pills and Brady’s star power, eMed is positioned to become a major player in the digital pharmacy space.